Literature DB >> 32993461

Thrombolysis in Cerebral Infarction 2b Reperfusions: To Treat or to Stop?

Johannes Kaesmacher1, Johanna M Ospel2,3, Thomas R Meinel4, Grégoire Boulouis5, Mayank Goyal3, Bruce C V Campbell6, Jens Fiehler7, Jan Gralla1,8, Urs Fischer4.   

Abstract

In patients undergoing mechanical thrombectomy, achieving complete (Thrombolysis in Cerebral Infarction 3) rather than incomplete successful reperfusion (Thrombolysis in Cerebral Infarction 2b) is associated with better functional outcome. Despite technical improvements, incomplete reperfusion remains the final angiographic result in 40% of patients according to recent trials. As most incomplete reperfusions are caused by distal vessel occlusions, they are potentially amenable to rescue strategies. While observational data suggest a net benefit of up to 20% in functional independence of incomplete versus complete reperfusions, the net benefit of secondary improvement from Thrombolysis in Cerebral Infarction 2b to 3 reperfusion might differ due to lengthier procedures and delayed reperfusion. Current strategies to tackle distal vessel occlusions consist of distal (microcatheter) aspiration, small adjustable stent retrievers, and administration of intra-arterial thrombolytics. While there are promising reports evaluating those techniques, all available studies show relevant limitations in terms of selection bias, single-center design, or nonconsecutive patient inclusion. Besides an assessment of risks associated with rescue maneuvers, we advocate that the decision-making process should also include a consideration of potential outcomes if complete reperfusion would successfully be achieved. These include (1) a futile angiographic improvement (hypoperfused territory is already infarcted), (2) an unnecessary angiographic improvement (the patient would not have developed infarction if no rescue maneuver was performed), and (3) a successful rescue maneuver with clinical benefit. Currently there is paucity of data on how these scenarios can be predicted and the decision whether to treat or to stop in a patient with incomplete reperfusion involves many unknowns. To advance the status quo, we outline current knowledge gaps and avenues of potential research regarding this clinically important question.

Entities:  

Keywords:  decision-making; endovascular; reperfusion; stroke; thrombectomy

Year:  2020        PMID: 32993461     DOI: 10.1161/STROKEAHA.120.030157

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  4 in total

1.  Per-pass analysis of recanalization and good neurological outcome in thrombectomy for stroke: Systematic review and meta-analysis.

Authors:  Jorge Arturo Larco; Mehdi Abbasi; Yang Liu; Sarosh Irfan Madhani; Adnan Hussain Shahid; Ramanathan Kadirvel; Waleed Brinjikji; Luis E Savastano
Journal:  Interv Neuroradiol       Date:  2021-07-06       Impact factor: 1.764

2.  Predictive Value of CT Perfusion Imaging on the Basis of Automatic Segmentation Algorithm to Evaluate the Collateral Blood Flow Status on the Outcome of Reperfusion Therapy for Ischemic Stroke.

Authors:  Qingsong Gong; Botao Yu; Mengjie Wang; Min Chen; Haowen Xu; Jianbo Gao
Journal:  J Healthc Eng       Date:  2021-11-11       Impact factor: 2.682

3.  Heterogeneity of the Relative Benefits of TICI 2c/3 over TICI 2b50/2b67 : Are there Patients who are less Likely to Benefit?

Authors:  Christoph C Kurmann; Adnan Mujanovic; Eike I Piechowiak; Tomas Dobrocky; Felix Zibold; Morin Beyeler; Jan Vynckier; David Seiffge; Thomas R Meinel; Pasquale Mordasini; Marcel Arnold; Urs Fischer; Jan Gralla; Johannes Kaesmacher
Journal:  Clin Neuroradiol       Date:  2022-01-06       Impact factor: 3.156

4.  Continuing early mTICI 2b recanalization may improve functional outcome but is associated with a higher risk of intracranial hemorrhage.

Authors:  Paul Steffen; Noel Van Horn; Rosalie McDonough; Milani Deb-Chatterji; Anna Christina Alegiani; Götz Thomalla; Jens Fiehler; Fabian Flottmann
Journal:  Front Neurol       Date:  2022-09-26       Impact factor: 4.086

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.